# US 2026/0085117 A1 · Antibodies Comprising Chimeric Constant Domains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085117 A1
- Document ID: US20260085117A1
- Status: Published application
- Kind: A1
- Application number: 19/398,913
- Filed: 2025-11-24
- Published: 2026-03-26
- Earliest claimed: 2013-02-01
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Samuel Davis; Eric Smith; Supriya Patel
- Web page: https://patentgrep.com/patent/US20260085117A1

## CPC

- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2887: {against CD20}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C12N 15/85: for animal cells
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/53: Hinge
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

## Claims

### Claim 1

A recombinant polypeptide comprising a heavy chain constant (CH) region comprising, from N-terminus to C-terminus, a CH1 domain, a chimeric hinge, a CH2 domain, and a CH3 domain wherein:
(a) the CH1 domain comprises the amino acid sequence DKKV or DKRV from positions 212 to 215 (EU numbering),
(b) the chimeric hinge comprises a human IgG1 or a human IgG4 upper hinge amino acid sequence from positions 216 to 227 (EU numbering) and a human IgG2 lower hinge amino acid sequence PCPAPPVA (SEQ ID NO: 3) from positions 228 to 236 (EU numbering),
(c) the CH2 domain comprises a human IgG4 CH2 domain amino acid sequence from positions 237 to 340 (EU numbering), and
(d) the CH3 domain comprises a human IgG1 or a human IgG4 CH3 domain sequence from positions 341 to 447 (EU numbering).

### Claim 2 (depends on 1)

The recombinant polypeptide of claim 1, wherein the CH region has an amino acid sequence at least 99% identical to any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 37, or SEQ ID NO: 38.

### Claim 3 (depends on 1)

The recombinant polypeptide of claim 1, wherein the CH1 domain comprises the amino acid sequence DKKV (SEQ ID NO: 4), and the chimeric hinge comprises the amino acid sequence EPKSCDKTHTCPPCPAPPVA (SEQ ID NO: 8).

### Claim 4 (depends on 1)

The recombinant polypeptide of claim 1, wherein the CH1 domain comprises the amino acid sequence DKRV (SEQ ID NO: 5), and the chimeric hinge comprises the amino acid sequence ESKYGPPCPPCPAPPVA (SEQ ID NO: 9).

### Claim 5 (depends on 1)

The recombinant polypeptide of claim 1, wherein the CH2 domain comprises the amino acid sequence SEQ ID NO: 10.

### Claim 6 (depends on 1)

The recombinant polypeptide of claim 1, wherein the CH3 domain comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 11, or SEQ ID NO: 12, SEQ ID NO: 41, and SEQ ID NO: 42.

### Claim 7 (depends on 1)

The recombinant polypeptide of claim 1, wherein the recombinant polypeptide is an antigen-binding protein.

### Claim 8 (depends on 1)

The recombinant polypeptide of claim 1, wherein the recombinant polypeptide is a receptor-Fc fusion protein.

### Claim 9 (depends on 1)

The recombinant polypeptide of claim 1, wherein the recombinant polypeptide is an antibody.

### Claim 10 (depends on 9)

The recombinant polypeptide of claim 9, wherein the antibody exhibits direct cytotoxic activity of less than 20% cytolysis, or less than 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable cytolysis, at an antibody concentration of at least 10 nM.

### Claim 11 (depends on 10)

The recombinant polypeptide of claim 10, wherein the direct cytotoxic activity is at least about 5-fold less, or at least about 10-fold less than the direct cytotoxic activity of a corresponding antibody comprising a wild-type IgG1 or wild-type IgG4 CH region.

### Claim 12

A recombinant polypeptide, wherein the polypeptide comprises N′-VD1-X1-Y1-Y2-X2-X3-C′, wherein:
(a) N′ is the N-terminus and C′ is the C-terminus of the polypeptide,
(b) VD1 is an amino acid sequence comprising an antigen-binding domain,
(c) X1 is an amino acid sequence comprising a domain selected from the group consisting of an IgG1 CH1 domain, an IgG4 CH1 domain, and at least positions 212-215 (EU numbering) of an IgG1 or IgG4 CH1 domain,
(d) Y1 comprises an amino acid sequence from positions 216-227 (EU numbering) of an IgG1 or IgG4 hinge region,
(e) Y2 comprises the human IgG2 lower hinge region amino acid sequence PCPAPPVA (SEQ ID NO: 3) from positions 228 to 236 (EU numbering),
(f) X2 is an amino acid sequence comprising an IgG4 CH2 domain, and
(g) X3 is an amino acid sequence comprising an IgG1 CH3 domain or an IgG4 CH3 domain.

### Claim 13 (depends on 12)

The recombinant polypeptide of claim 12, wherein the polypeptide comprises an amino acid sequence at least 99% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 37, or SEQ ID NO: 38.

### Claim 14 (depends on 12)

The recombinant polypeptide of claim 12, wherein X1 comprises the amino acid sequence DKKV (SEQ ID NO: 4), and Y1-Y2 comprises a chimeric hinge consisting of the amino acid sequence EPKSCDKTHTCPPCPAPPVA (SEQ ID NO: 8).

### Claim 15 (depends on 12)

The recombinant polypeptide of claim 12, wherein X1 comprises the amino acid sequence DKRV (SEQ ID NO: 5), and Y1-Y2 comprises a chimeric hinge consisting of the amino acid sequence ESKYGPPCPPCPAPPVA (SEQ ID NO: 9).

### Claim 16 (depends on 12)

The recombinant polypeptide of claim 12, wherein X2 comprises the amino acid sequence of SEQ ID NO: 10.

### Claim 17 (depends on 12)

The recombinant polypeptide of claim 12, wherein X3 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 41, and SEQ ID NO: 42.

### Claim 18 (depends on 12)

The recombinant polypeptide of claim 12, wherein the recombinant polypeptide is an isolated antigen-binding protein.

### Claim 19 (depends on 12)

The recombinant polypeptide of claim 12, wherein the recombinant polypeptide is a receptor-Fc fusion protein.

### Claim 20 (depends on 12)

The recombinant polypeptide of claim 12, wherein the recombinant polypeptide is an isolated antibody.

### Claim 21 (depends on 20)

The recombinant polypeptide of claim 20, wherein the antibody exhibits direct cytotoxic activity of less than 20% cytolysis, or less than 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable cytolysis, at an antibody concentration of at least 10 nM.

### Claim 22 (depends on 21)

The recombinant polypeptide of claim 21, wherein the direct cytotoxic activity is at least about 5-fold less, or at least about 10-fold less than the direct cytotoxic activity of a corresponding antibody comprising a wild-type IgG1 or wild-type IgG4 CH region.

### Claim 23 (depends on 1, 12)

A composition comprising a recombinant polypeptide of claim 1 or claim 12.

### Claim 24 (depends on 1, 12)

A nucleic acid molecule encoding a recombinant polypeptide of claim 1 or claim 12.

### Claim 25 (depends on 24)

The nucleic acid molecule of claim 24, wherein the recombinant polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 30, and SEQ ID NO: 31, SEQ ID NO: 37, and SEQ ID NO: 38.

### Claim 26 (depends on 24)

The nucleic acid molecule of claim 24 having a nucleotide sequence greater than 99% sequence identity to the nucleotide sequence of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 35, or SEQ ID NO: 36.

### Claim 27 (depends on 25)

The nucleic acid molecule of claim 25 comprising a nucleotide sequence selected the group consisting of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 32, and SEQ ID NO: 33, SEQ ID NO: 35, and SEQ ID NO: 36.

### Claim 28 (depends on 25)

A vector comprising a nucleic acid molecule claim 25.

### Claim 29 (depends on 28)

The vector of claim 28, wherein the nucleic acid molecule is operatively linked to an expression control sequence suitable for expression in a host cell.

### Claim 30 (depends on 29)

The vector of claim 29, wherein the expression control sequence comprises a promoter selected from the group consisting of SV40, CMV, CMV-IE, CMV-MIE, UbC, RSV, SL3-3, MMTV, Ubi and HIV LTR.

### Claim 31 (depends on 29)

The vector of claim 29, wherein the expression control sequence comprises an expression cassette selected from the group consisting of TetR-ERLBDT2 fusion gene driven by the CMV-MIE promoter, blasticidin resistance gene driven by the SV40 promoter, and Arc-ERLBDT2 fusion gene driven by the CMV-MIE promoter.

### Claim 32 (depends on 30)

The vector of claim 30, wherein the promoter is a CMV-MIE/TetO or CMV-MIE/Arc hybrid promoter.

### Claim 33 (depends on 30)

The vector of claim 30, comprising one or more selectable marker genes selected from the group consisting of bla, bls, BSD, bsr, Sh ble, hpt, tetR, tetM, npt, kanR and pac.

### Claim 34 (depends on 24)

A cell comprising a nucleic acid of claim 24.

### Claim 35 (depends on 28)

A cell comprising the vector of claim 28.

### Claim 36 (depends on 34)

The cell of claim 34, wherein the nucleic acid is integrated into the genome of the cell.

### Claim 37 (depends on 36)

The cell of claim 36 comprising a nucleic acid encoding a protein expression enhancer.

### Claim 38 (depends on 37)

The cell of claim 37 comprising a nucleic acid encoding an XBP polypeptide.

### Claim 39 (depends on 34)

The cell of claim 34, wherein the cell is a eukaryotic cell.

### Claim 40 (depends on 34)

The cell of claim 34, wherein the cell is an animal cell.

### Claim 41 (depends on 34)

The cell of claim 34, wherein the cell is a mammalian cell.

### Claim 42 (depends on 34)

The cell claim 34, wherein the cell is a CHO cell.

### Claim 43 (depends on 34)

The cell of claim 34, wherein the cell is a CHO-K1 cell.
